معرفی
Wenshe Liu is the Harry E. Bovay, Jr. Endowed Chair in Chemistry and Professor at Texas A&M University, affiliated with the Department of Biochemistry & Biophysics and the Institute of Biosciences & Technology. His research integrates chemical biology, organic chemistry, and molecular biology to develop novel therapeutics targeting cancer and viral pathogens like SARS-CoV-2. Key techniques include genetic code expansion (via pyrrolysyl-tRNA synthetase systems), phage display with noncanonical peptides, and epigenetic histone modification studies.
Education: B.S. (Peking University, 2000), Ph.D. (UC Davis, 2005), Postdoc (Scripps Research Institute, 2007). Awards include the Presidential Impact Fellow, Gradipore Chair in Chemistry, and ACS Chemical Biology Most Prolific Author (2017).
Research focuses on: (1) SARS-CoV-2 drug discovery targeting Spike protein, 3CLpro, and PLpro; (2) genetic code expansion for ncAA incorporation (over 80 ncAAs developed); (3) epigenetic histone modification studies using site-specific acylation/methylation; (4) phage-displayed cyclic peptide libraries for drug discovery. Current projects include PROTAC development for epigenetic regulators and chemo-genetic switches for CAR T-cell therapy safety.
Publications highlight high-impact work in Nature, Journal of the American Chemical Society, and Nature Communications, with over 150 articles. The lab operates across Texas A&M campuses in College Station and Houston, emphasizing translational research in immunotherapy and antiviral strategies.
